scispace - formally typeset
S

Samreen Ijaz

Researcher at Public Health England

Publications -  167
Citations -  9249

Samreen Ijaz is an academic researcher from Public Health England. The author has contributed to research in topics: Hepatitis E & Hepatitis E virus. The author has an hindex of 43, co-authored 145 publications receiving 7387 citations. Previous affiliations of Samreen Ijaz include University College London & NHS Blood and Transplant.

Papers
More filters
Journal ArticleDOI

Genetic mechanisms of critical illness in Covid-19.

Erola Pairo-Castineira, +1449 more
- 04 Mar 2021 - 
TL;DR: The GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2244 critically ill Covid-19 patients from 208 UK intensive care units is reported, finding evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease.
Journal ArticleDOI

Hepatitis E: an emerging infection in developed countries

TL;DR: Patients with unexplained hepatitis should be tested for hepatitis E, whatever their age or travel history, and the source and route of infection remain uncertain, but it might be a porcine zoonosis.
Journal ArticleDOI

Persistent carriage of hepatitis E virus in patients with HIV infection.

TL;DR: A 48-year-old bisexual white male who was infected with human immunodeficiency virus type 1 (HIV-1) and who had elevated liver enzymes and infection with hepatitis E virus for at least 24 months is described.
Journal ArticleDOI

Hepatitis E virus in blood components: a prevalence and transmission study in southeast England

TL;DR: The findings suggest that HEV genotype 3 infections are widespread in the English population and in blood donors and an agreed policy is needed for the identification of patients with persistent HEV infection, irrespective of origin, so that they can be offered antiviral therapy.
Journal ArticleDOI

A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries

TL;DR: The results suggest that published studies of HEV seroprevalence using the GL assay have underestimated the true figure and that a properly validated method is required to make meaningful comparisons of HEv serop revalence between populations.